Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Trends in antimicrobial drug development: implications for the future.

Brad Spellberg1, John H Powers, Eric P Brass

  • 1Research and Education Institute and Department of Medicine, Harbor-University of California, Los Angeles Medical Center, Torrance, California 90502, USA.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|May 6, 2004
PubMed
Summary

The development of new antimicrobial agents is declining despite a growing need due to drug resistance and new infections. Pharmaceutical companies are reducing research, leading to fewer new antibacterial drugs approved.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Procalcitonin-An Enigmatic Anxiolytic Biomarker.

JAMA network open·2026
Same author

Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same author

Characterizing the in vitro and in vivo effect of bicarbonate on azithromycin activity against Acinetobacter baumannii.

PloS one·2026
Same author

Universal high-dose meropenem for antimicrobial-resistant Gram-negative infections: evidence or overreach?

European journal of hospital pharmacy : science and practice·2026
Same author

Evidence Over Eminence: Rethinking Specialty Guidelines Amid the ATS-IDSA Debate.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

A Once-in-a-Generation Transformation at an Academic Public Hospital During Federal Funding Uncertainty.

Journal of healthcare leadership·2026

Area of Science:

  • Pharmaceutical Science
  • Infectious Diseases
  • Drug Development

Background:

  • Increasing prevalence of multidrug-resistant pathogens and emerging infectious diseases necessitates novel antimicrobial therapies.
  • A concerning trend of reduced investment in anti-infective research by pharmaceutical companies is observed.
  • The potential for bioterrorism using multidrug-resistant agents highlights the urgency for new drug development.

Purpose of the Study:

  • To analyze trends in the development and approval of new antimicrobial agents.
  • To assess the pipeline of new antibacterial drugs in major pharmaceutical and biotechnology companies.

Main Methods:

  • Evaluation of United States Food and Drug Administration (FDA) databases for approved drugs.
  • Analysis of research and development programs from leading global pharmaceutical and biotechnology firms.

Related Experiment Videos

Main Results:

  • A 56% decrease in FDA approvals for new antibacterial agents was observed between 1998-2002 and 1983-1987.
  • New antibacterial agents represent only a small fraction (6 out of 506) of drugs in development pipelines.
  • The overall development of new antimicrobial agents is showing a downward trend.

Conclusions:

  • There is a critical and growing need for new antimicrobial agents.
  • The declining development of these essential medicines poses a significant public health risk.
  • Incentives and strategies are required to stimulate the development of novel antimicrobial drugs.